Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 84 articles:
HTML format



Single Articles


    October 2021
  1. FRIEDRICH RE, Madani E
    Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer.
    Anticancer Res. 2021;41:5081-5087.
    PubMed     Abstract available


  2. VAHAAHO N, Hakamies-Blomqvist L, Blomqvist C, Kellokumpu-Lehtinen PL, et al
    Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients.
    Anticancer Res. 2021;41:5045-5052.
    PubMed     Abstract available


  3. TAKASHIMA T, Nishimura S, Kawajiri H, Mizuyama Y, et al
    An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
    Anticancer Res. 2021;41:5007-5014.
    PubMed     Abstract available


  4. WU NF, Yamamoto J, Aoki Y, Masaki N, et al
    The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Anticancer Res. 2021;41:4715-4718.
    PubMed     Abstract available


    September 2021
  5. VANNI G, Pellicciaro M, Combi F, Papi S, et al
    Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study.
    Anticancer Res. 2021;41:4535-4542.
    PubMed     Abstract available


  6. WANG YC, Wang ZH, Shen TC, Chang WS, et al
    Contribution of Interleukin-12A Genotypes to Breast Cancer Risk.
    Anticancer Res. 2021;41:4387-4393.
    PubMed     Abstract available


  7. LIAO CL, Peng SF, Chen JC, Chen PY, et al
    Allyl Isothiocyanate Induces DNA Damage and Impairs DNA Repair in Human Breast Cancer MCF-7 Cells.
    Anticancer Res. 2021;41:4343-4351.
    PubMed     Abstract available


  8. YONEMITSU K, Miyasato Y, Shiota T, Shinchi Y, et al
    Soluble Factors Involved in Cancer Cell-Macrophage Interaction Promote Breast Cancer Growth.
    Anticancer Res. 2021;41:4249-4258.
    PubMed     Abstract available


  9. WATANABE J, Nakamoto S, Sugino T
    The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution.
    Anticancer Res. 2021;41:4619-4627.
    PubMed     Abstract available


  10. RIFFEL J, Kannengiesser S, Schoenberg SO, Kaiser AK, et al
    T2-weighted Imaging of the Breast at 1.5T Using Simultaneous Multi-slice Acceleration.
    Anticancer Res. 2021;41:4423-4429.
    PubMed     Abstract available


    August 2021
  11. YAMADA M, Kubo M, Yamamoto H, Yamashita N, et al
    Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
    Anticancer Res. 2021;41:4143-4149.
    PubMed     Abstract available


  12. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy.
    Anticancer Res. 2021;41:4133-4141.
    PubMed     Abstract available


  13. OGINO M, Fujii T, Koibuchi Y, Nakazawa Y, et al
    Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.
    Anticancer Res. 2021;41:3899-3904.
    PubMed     Abstract available


  14. STELLER D, Simon R, VON Bialy R, Hakim SG, et al
    Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Anticancer Res. 2021;41:3917-3923.
    PubMed     Abstract available


  15. KIM H, Gim JA, Kim CY, Kim A, et al
    Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing.
    Anticancer Res. 2021;41:3779-3787.
    PubMed     Abstract available


    July 2021
  16. YAMANOUCHI K, Maeda S, Takei D, Koga Y, et al
    Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer.
    Anticancer Res. 2021;41:3625-3634.
    PubMed     Abstract available


  17. TANG A, Mooney CM, Beattie G, Cohan CM, et al
    Health Equity Within Inequity: Timing of Diagnostic Breast Cancer Care in an Underserved Medical Population.
    Anticancer Res. 2021;41:3607-3613.
    PubMed     Abstract available


  18. SUZUKI C, Yamada A, Adachi S, Shima H, et al
    Bromodomain-containing Protein 4 Is a Favourable Prognostic Factor in Breast Cancer Patients.
    Anticancer Res. 2021;41:3597-3606.
    PubMed     Abstract available


  19. RAJBONGSHI L, Noh MH, Kim YS, Hur DY, et al
    Effects of Epstein-Barr Virus Infection on the Response of Human Breast Cancer Cells to Nicotine.
    Anticancer Res. 2021;41:3449-3458.
    PubMed     Abstract available


  20. VIEIRA JF, Peixoto AP, Murta EFC, Michelin MA, et al
    Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases.
    Anticancer Res. 2021;41:3419-3427.
    PubMed     Abstract available


  21. KIM CY, Kim YC, Oh JH, Kim MH, et al
    HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
    Anticancer Res. 2021;41:3409-3417.
    PubMed     Abstract available


  22. MARCHICA P, D'Arpa S, Magno S, Rossi C, et al
    Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art.
    Anticancer Res. 2021;41:3233-3246.
    PubMed     Abstract available


    June 2021
  23. KIM K, Chun M, Jin H, Jung W, et al
    Inter-institutional Variation in Intensity-modulated Radiotherapy for Breast Cancer in Korea (KROG 19-01).
    Anticancer Res. 2021;41:3145-3152.
    PubMed     Abstract available


  24. AKAGI H, Shimada A, Chin K, Domoto H, et al
    Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient.
    Anticancer Res. 2021;41:3139-3144.
    PubMed     Abstract available


  25. MIKI M, Takao S, Konishi M, Shigeoka Y, et al
    Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
    Anticancer Res. 2021;41:3121-3126.
    PubMed     Abstract available


  26. KRAWCZYK N, Janowski K, Banys-Paluchowski M, Staebler A, et al
    The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2021;41:2849-2858.
    PubMed     Abstract available


  27. WALL TP, Crowley PD, Buggy DJ
    The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour In Vitro.
    Anticancer Res. 2021;41:2835-2840.
    PubMed     Abstract available


  28. OHLINGER R, Alwafai Z, Paepke S, Zygmunt M, et al
    Patient Quality of Life After Subpectoral Implant-based Breast Reconstruction With Synthetic or Biological Materials.
    Anticancer Res. 2021;41:3075-3082.
    PubMed     Abstract available


    May 2021
  29. ORSARIA P, Grasso A, Ippolito E, Pantano F, et al
    Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Anticancer Res. 2021;41:2697-2709.
    PubMed     Abstract available


  30. VANNI G, Pellicciaro M, Materazzo M, Pedini D, et al
    Advanced Stages and Increased Need for Adjuvant Treatments in Breast Cancer Patients: The Effect of the One-year COVID-19 Pandemic.
    Anticancer Res. 2021;41:2689-2696.
    PubMed     Abstract available


  31. RADES D, Narvaez CA, Dziggel L, Tvilsted S, et al
    Sleep Disorders in Patients With Breast Cancer Prior to a Course of Radiotherapy - Prevalence and Risk Factors.
    Anticancer Res. 2021;41:2489-2494.
    PubMed     Abstract available


  32. CHEN KY, Chien WC, Liao JM, Tsai CW, et al
    Contribution of Interleukin-10 Genotype to Triple Negative Breast Cancer Risk.
    Anticancer Res. 2021;41:2451-2457.
    PubMed     Abstract available


  33. ALAAELDIN R, Abuo-Rahma GEA, Zhao QL, Fathy M, et al
    Modulation of Apoptosis and Epithelial-Mesenchymal Transition E-cadherin/TGF-beta/Snail/TWIST Pathways by a New Ciprofloxacin Chalcone in Breast Cancer Cells.
    Anticancer Res. 2021;41:2383-2395.
    PubMed     Abstract available


  34. JINIH M, Wang JH, Pfirrmann RW, O'Leary DP, et al
    Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells.
    Anticancer Res. 2021;41:2247-2256.
    PubMed     Abstract available


  35. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available


    April 2021
  36. HAYASHI K, Tamura M, Nagasaki E, Yoshii Y, et al
    A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer.
    Anticancer Res. 2021;41:2193-2195.
    PubMed     Abstract available


  37. SASAKI R, Horimoto Y, Yanai Y, Kurisaki-Arakawa A, et al
    Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:2133-2140.
    PubMed     Abstract available


  38. VANNI G, Materazzo M, Pellicciaro M, Amir S, et al
    Breast Textured Implants Determine Early T-helper Impairment: BIAL2.20 Study.
    Anticancer Res. 2021;41:2123-2132.
    PubMed     Abstract available


  39. JOSEPH WJ, Bustos SS, Losee JE, Rubin JP, et al
    The Impact of the COVID-19 Pandemic on Breast Reconstruction Practices in the United States.
    Anticancer Res. 2021;41:1903-1908.
    PubMed     Abstract available


  40. RIGAKOS G, Razis E, Koliou GA, Oikonomopoulos G, et al
    Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
    Anticancer Res. 2021;41:1793-1802.
    PubMed     Abstract available


  41. OHLINGER R, Nawroth F, Kohlmann T, Alwafai Z, et al
    Retrospective Study of Radiotherapy Impact on the Outcome of Material-assisted Implant-based Subpectoral Breast Reconstruction.
    Anticancer Res. 2021;41:2017-2024.
    PubMed     Abstract available


  42. ZWICKER F, Hoefel S, Kirchner C, Huber PE, et al
    Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge.
    Anticancer Res. 2021;41:1909-1920.
    PubMed     Abstract available


    March 2021
  43. YAMAMOTO S, Narui K, Ishikawa T, Adachi S, et al
    First-line Gemcitabine Versus Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study.
    Anticancer Res. 2021;41:1671-1676.
    PubMed     Abstract available


  44. FERINI G, Molino L, Tripoli A, Valenti V, et al
    Anatomical Predictors of Dosimetric Advantages for Deep-inspiration-breath-hold 3D-conformal Radiotherapy Among Women With Left Breast Cancer.
    Anticancer Res. 2021;41:1529-1538.
    PubMed     Abstract available


  45. KRAJNAK S, Loewe A, Battista MJ, Hasenburg A, et al
    The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells.
    Anticancer Res. 2021;41:1243-1250.
    PubMed     Abstract available


  46. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available


    February 2021
  47. INOUE S, Kawaida H, Saito R, Nakayama Y, et al
    Clinical Significance of Past History of Breast Cancer Screening for the Prognosis of Triple Negative Breast Cancer.
    Anticancer Res. 2021;41:1077-1082.
    PubMed     Abstract available


  48. YAMADA A, Nakazawa K, Akazawa K, Narui K, et al
    Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study.
    Anticancer Res. 2021;41:1063-1068.
    PubMed     Abstract available


  49. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:949-954.
    PubMed     Abstract available


  50. OKAZAKI M, Mogushi K, Denda-Nagai K, Fujihira H, et al
    Biological and Clinicopathological Implications of Beta-3-N-acetylglucosaminyltransferase 8 in Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:845-858.
    PubMed     Abstract available


  51. RAICA M, Ceausu AR, Cimpean AM, ComSa S, et al
    Chloride Intracellular Channel Protein 1 (CLIC1), E-cadherin and P-cadherin Define Distinct Subclasses of HER2, Luminal B and Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:795-802.
    PubMed     Abstract available


  52. SHARIF-ASKARI FS, Al-Khayyal N, Talaat I, Sharif-Askari NS, et al
    Immunohistochemical Assessment of TNFAIP3/A20 Expression Correlates With Early Tumorigenesis in Breast Cancer.
    Anticancer Res. 2021;41:739-745.
    PubMed     Abstract available


  53. PAPADAKI MA, Aggouraki D, Vetsika EK, Xenidis N, et al
    Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Anticancer Res. 2021;41:661-670.
    PubMed     Abstract available


  54. UNGER J, Rutkowski R, Kohlmann T, Paepke S, et al
    Potential Risk Factors Influencing the Formation of Postoperative Seroma After Breast Surgery - A Prospective Study.
    Anticancer Res. 2021;41:859-867.
    PubMed     Abstract available


  55. WALKER RR, Gallegos KM, Bratton MR, Lemieux KP, et al
    Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade.
    Anticancer Res. 2021;41:583-599.
    PubMed     Abstract available


    January 2021
  56. SCHMIDT M, KUmmel S, Ruf-Doerdelmann A, Distelrath A, et al
    Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin((R))) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
    Anticancer Res. 2021;41:485-496.
    PubMed     Abstract available


  57. OBA T, Maeno K, Ono M, Ito T, et al
    Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
    Anticancer Res. 2021;41:445-452.
    PubMed     Abstract available


  58. SAGARA M, Miyamoto S, Itoh S, Soda Y, et al
    Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Anticancer Res. 2021;41:81-89.
    PubMed     Abstract available


  59. CHOI YE, Sung K, Dong KS, Kim HJ, et al
    Dosimetric Impact of Respiratory Motion During Breast Intensity-modulated Radiation Therapy Using Four-dimensional Dose Calculations.
    Anticancer Res. 2021;41:417-427.
    PubMed     Abstract available


  60. IBRAGIMOVA MK, Tsyganov MM, Pevzner AM, Litviakov NV, et al
    Transcriptome of Breast Tumors With Different Amplification Status of the Long Arm of Chromosome 8.
    Anticancer Res. 2021;41:187-195.
    PubMed     Abstract available


  61. ONAGA C, Tamori S, Motomura H, Ozaki A, et al
    High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers.
    Anticancer Res. 2021;41:43-54.
    PubMed     Abstract available


    December 2020
  62. VANNI G, Tazzioli G, Pellicciaro M, Materazzo M, et al
    Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients.
    Anticancer Res. 2020;40:7119-7125.
    PubMed     Abstract available


  63. MACAIONE I, Galvano A, Graceffa G, Lupo S, et al
    Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer.
    Anticancer Res. 2020;40:7083-7088.
    PubMed     Abstract available


  64. TSAI CL, Tsai CW, Chang WS, Su CH, et al
    Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility.
    Anticancer Res. 2020;40:6743-6749.
    PubMed     Abstract available


  65. YAMADA A, Suzuki C, Shima H, Kida K, et al
    Aldehyde Dehydrogenase 1-related Genes in Triple-negative Breast Cancer Investigated Using Network Analysis.
    Anticancer Res. 2020;40:6733-6742.
    PubMed     Abstract available


  66. NIWA Y, Asano M, Nakagawa T, France D, et al
    Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Anticancer Res. 2020;40:6699-6712.
    PubMed     Abstract available


  67. ANAYA-EUGENIO GD, Eggers NA, Ren Y, Rivera-ChAvez J, et al
    Apoptosis Induced by (+)-Betulin Through NF-kappaB Inhibition in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2020;40:6637-6647.
    PubMed     Abstract available


  68. ROBINSON AGJ, Kanaan YM, Copeland RL
    Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2020;40:6623-6635.
    PubMed     Abstract available


    November 2020
  69. NUZZO M, Ursini LA, Patani F, Rosa C, et al
    Using the Bolus in Post-mastectomy Radiation Therapy (PMRT): A National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Breast Cancer Group.
    Anticancer Res. 2020;40:6505-6511.
    PubMed     Abstract available


  70. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
    Anticancer Res. 2020;40:6417-6428.
    PubMed     Abstract available


  71. AUGUSTINE TN, Duarte R, Candy GP
    Breast Cancer Cells Induce a Pro-inflammatory Response to Mitigate Immune Mediation in a 3D Culture Model.
    Anticancer Res. 2020;40:6179-6193.
    PubMed     Abstract available


  72. SHIMODA M, Kim SJ, Tokuda Y, Sota Y, et al
    Effect of Computer-aided Detection System Use on the Duration of MRI-guided Biopsy of the Breast.
    Anticancer Res. 2020;40:6437-6441.
    PubMed     Abstract available


  73. STOPE MB, Benouahi R, Sander C, Haralambiev L, et al
    Protherapeutic Effects and Inactivation of Mammary Carcinoma Cells by a Medical Argon Plasma Device.
    Anticancer Res. 2020;40:6205-6212.
    PubMed     Abstract available


    October 2020
  74. SHINDEN Y, Nagata A, Nomoto Y, Saho H, et al
    Surgical Resection With Pedicled Rotation Flap for Post-mastectomy Locoregional Breast Cancer Recurrence.
    Anticancer Res. 2020;40:5739-5742.
    PubMed     Abstract available


  75. YENILMEZ EN, Genc D, Farooqi AA, Tunoglu S, et al
    Mesenchymal Stem Cells Combined With IFNgamma Induce Apoptosis of Breast Cancer Cells Partially Through TRAIL.
    Anticancer Res. 2020;40:5641-5647.
    PubMed     Abstract available


  76. MARGAN MM, Cimpean AM, Ceausu AR, Raica M, et al
    Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes.
    Anticancer Res. 2020;40:5557-5566.
    PubMed     Abstract available


  77. LI CL, Huang CW, Ko CJ, Fang SY, et al
    Curcumol Suppresses Triple-negative Breast Cancer Metastasis by Attenuating Anoikis Resistance via Inhibition of Skp2-mediated Transcriptional Addiction.
    Anticancer Res. 2020;40:5529-5538.
    PubMed     Abstract available


  78. SCATOZZA F, D'Amore A, Fontanella RA, DE Cesaris P, et al
    Toll-Iike Receptor-3 Activation Enhances Malignant Traits in Human Breast Cancer Cells Through Hypoxia-inducible Factor-1alpha.
    Anticancer Res. 2020;40:5379-5391.
    PubMed     Abstract available


  79. WAZIR U, Mokbel K
    De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
    Anticancer Res. 2020;40:5351-5354.
    PubMed     Abstract available


  80. KIM SW, Kim HS, Na K
    Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
    Anticancer Res. 2020;40:5925-5932.
    PubMed     Abstract available


  81. PARK JH, Ahn JH, Kim JE, Jung KH, et al
    Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Anticancer Res. 2020;40:5883-5893.
    PubMed     Abstract available


  82. YILDIRIM E, Bektas S, Gundogar O, Findik D, et al
    The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
    Anticancer Res. 2020;40:5649-5657.
    PubMed     Abstract available


  83. PERNICONE N, Peretz L, Grinshpon S, Listovsky T, et al
    MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis.
    Anticancer Res. 2020;40:5471-5480.
    PubMed     Abstract available


    September 2020
  84. NASIR UM, Mozeika AM, Sayan M, Jan I, et al
    Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.
    Anticancer Res. 2020;40:5291-5294.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: